Medicinal
Patient approved to receive psilocybin therapy for MDD
Braxia Scientific will deliver the therapy through Health Canada’s Special Access Program (SAP).

Published
1 month agoon

Braxia Scientific has received approval from Health Canada to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder (MDD) in Ontario.
The psilocybin-assisted therapy will be delivered through Braxia’s wholly owned subsidiary Canadian Rapid Treatment Centre of Excellence (CRTCE).
The approval is Braxia‘s first psilocybin-assisted therapy treatment using Health Canada’s SAP, however, the company was the first to receive Health Canada approval for a multi-dose psilocybin-assisted therapy clinical trial in July 2021.
Chief Medical and Scientific Officer at Braxia Scientific, Dr Joshua Rosenblat, commented: “Being among the first to begin delivering psilocybin-assisted therapy treatments in Canada last year through our clinical trial, we have developed and optimised the infrastructure, including rigorous training for our therapists through our Braxia Institute, to provide a positive patient experience while optimising outcomes.”
“To our knowledge, this is the first Health Canada SAP approval for psilocybin-assisted therapy for a person with Major Depressive Disorder in Ontario.
“My patient and I are extremely grateful for this opportunity to access this promising treatment. Health Canada was very responsive to this request, promptly providing the Letter of Authorization.
“This rapid approval stands in contrast to the previously required Section 56 exemptions that could take years to fully process. Allowing use of the SAP will be incredibly beneficial for patients in need of this treatment that are unable to receive it through psychedelic clinical trials.”
Chairman and CEO of Braxia Scientific, Dr Roger McIntyre, commented: “Since opening our first clinic in 2018, in Toronto, Canada, our focus has been on creating a true centre of excellence for people living and suffering with depression to gain access to the most effective treatments.
“Our ability to deliver psilocybin-assisted therapy is an important step in our journey to achieving our vision of finding a cure for depression.
“The experience of our therapists who have already delivered this novel treatment in multiple doses to multiple patients in our ongoing psilocybin trial, combined with data we’ve collected to date and expect to read out in the coming weeks, provides an excellent opportunity for new applicants to receive access to the most advanced clinical protocols and care to achieve best outcomes in this field.
“In addition to providing access to innovative treatments for depression, Braxia Scientific is a leader in comprehensive research, development and best-practices implementation of psilocybin, ketamine and related agents.”
You may like
Silo Pharma to utilise psilocybin for autoimmune diseases
Study to investigate macro and microdoses of psychedelic compounds
World first study looks at application of virtual reality and psychedelics
Numinus receives Health Canada SAP approval for psilocybin therapy
Clerkenwell Health is launching a free UK psychedelic therapist training programme
Phase III trail of MDMA therapy for PTSD fully enroled
Medicinal
Silo Pharma to utilise psilocybin for autoimmune diseases
The company has announced it is expanding its license agreement and patent portfolio.

Published
3 days agoon
24th June 2022
Silo Pharma has entered into a commercial evaluation license agreement (CELA) for next-gen liposomes therapeutics to target multiple diseases, including autoimmune disorders.
Silo Pharma has expanded its CELA with the University of Maryland Baltimore (UMB) for its next-generation liposomal peptide targeting autoimmune diseases.
CEO of Silo Pharma, Eric Weisblum, commented: “We are delighted to expand our partnership with UMB. Pre-clinical testing of these peptides has shown positive results in animal studies.
“The three-phage peptides we identified specifically target inflamed vascular endothelium of arthritic joints in an adjuvant-induced arthritis rat model.”
Weisblum stated that to test the therapeutic effect of the peptides, arthritic Lewis rats (n=4/group) were injected intravenously with one of the peptides or PBS either at the onset or just following the onset of arthritis.
“The rats were monitored regularly for disease severity and were assigned an “arthritic score.” The results show treatment of arthritic Lewis rats with two of the three phage-encoded peptides (NQR and RGD) suppresses adjuvant arthritis, with RGD producing the most robust effect,” he said.
“Therefore, phage peptides ADK homes to the synovial vasculature of the inflamed joint, while phage peptides NQR and RGD both home to this area of the inflamed joint and have a therapeutic effect in a rat model of arthritis.”
Silo Pharma’s drug – SPU-21, arthritogenic joint homing peptides utilising psilocybin – has demonstrated it significantly inhibited arthritic progression in the animal model, and the company is carrying out further studies at UMB.
It highlights on its website that the ability of the peptides to target inflamed epithelium suggest they could be used to target drug delivery.
It notes that: “This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis.
“They could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides can be used to treat autoimmune diseases, including but not limited to RA [rheumatoid arthritis].”
With the global market for autoimmune disease therapeutics projected to be over $150bn by 2025, Weisblum stated that the company believes the issued patent portfolio that comes with these assets allows Silo to further advance its value to investors and future partners.
Medicinal
Application submitted for trial exploring LSD analogue for migraines

Published
5 days agoon
22nd June 2022
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
The company is aiming to begin a Phase 1 clinical trial of NYPRG-101, which is being developed for the prevention of migraines.
The trial would be a Phase 1, single center, randomised, double blind, placebo controlled, single ascending dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of NYPRG-101 (in healthy adult participants.
NYPRG-101, also referred to in the literature as BOL-148, is a non-hallucinogenic analogue of LSD, differing by only one atom.
First synthesised at Sandoz by Albert Hofmann in 1957, BOL-148 was used as a placebo in early LSD trials. BOL-148 has been administered to more than 150 humans (126 healthy volunteers and 28 patients) in clinical and experimental settings since the 1950s, with most of the research occurring prior to 1970. In these early studies, BOL-148 was observed to be non-hallucinogenic.
Founder and CEO of Ceruvia Lifesciences, Carey Turnbull, commented: “This is another exciting milestone in the roll-out of our clinical drug development program and builds on our longstanding relationship with Harvard Medical School to investigate the use of BOL-148 to treat headache disorders.
“Migraine, which affects approximately 15 per cent of the population and disproportionately impacts women, is associated with significant psychosocial burden and disability. Results from our IND-enabling pre-clinical toxicology work as well as research conducted with human subjects prior to the 1970s, indicate a positive safety profile for NYPRG-101.
“We believe that this molecule has great potential to provide meaningful relief to those suffering from migraine.”
This Phase 1 single ascending dose trial, to be held at a single clinical research site in the United States, will evaluate the safety, tolerability, pharmacokinetics and effects on neurocognitive functioning of healthy adult participants.
Medicinal
New plant medicine retreat series launched in Jamaica
Dimensions has launched ‘ASCEND’ – a series of psychedelic-assisted experiences.
Published
2 weeks agoon
15th June 2022By
chn_admin
Dimensions has launched its new international plant medicine retreat series in Jamaica.
The new ASCEND programme will combine legal plant medicine experiences with immersive luxury hospitality on the Good Hope Estate in Trelawny, Jamaica
Led by Dimensions’ chief clinical officer, Jesse Hanson, PhD, the ASCEND programme will span 11 weeks, including four weeks of preparation, one week of onsite practices and six weeks of post-retreat integration.
This will ensure that participants maximise their transformational experiences, as well as have a clear plan and path to sustain their life improvements.
Christopher Dawson, co-founder and CEO of Dimensions, commented: “We are relentless in the pursuit of our mission, which is Retreat, Reset, Transform.
“The ASCEND program has been carefully designed by our expert teams to offer the very highest standards in self-betterment in pristine, natural environments to maximise our guests’ journeys to wellbeing, and ensure that participants receive personalised experiences that initiate lasting personal growth.”
Dimensions’ Chief Clinical Officer, Jesse Hanson, PhD, commented: “The launch of the Jamaica ASCEND retreats is an ideal complement to the retreat experience that we will be offering at our flagship Dimensions Algonquin Highlands location in Ontario, Canada, and future retreats that we are developing in Costa Rica and Mexico.
“This a significant milestone as we continue to expand our diverse programming with a focus on the intersection of luxury hospitality, modern science, and plant medicine.”
The ASCEND program combines ancient practices with modern neuroscience while utilising the practices of poly-vagal theory with psychedelic medicine to deliver a uniquely integrated guest experience in an intimate and safe environment.
The Good Hope Estate is set on a 2000-acre historical property with hills, vales and a river running through its tropical landscape, underscoring Dimensions’ belief in the importance and role of nature in the healing experience.
The first two retreat experiences will take place from Friday, 30 September to Friday, 7 October, 2022 and Saturday, 10 December to Saturday, 17 December, 2022.
Recent Articles
- Silo Pharma to utilise psilocybin for autoimmune diseases
- Study to investigate macro and microdoses of psychedelic compounds
- Application submitted for trial exploring LSD analogue for migraines
- FDA clears psilocybin for government-funded smoking cessation trial
- Alliance launches to advance psychedelic healthcare in Europe
- Ohio State launches new academic centre for psychedelic research
Trending
- Silo Pharma to utilise psilocybin for autoimmune diseases
- Study to investigate macro and microdoses of psychedelic compounds
- Application submitted for trial exploring LSD analogue for migraines
- FDA clears psilocybin for government-funded smoking cessation trial
- Alliance launches to advance psychedelic healthcare in Europe
Trending
- News9 months ago
Could Italy decriminalise psychotropic substance cultivation?
- News11 months ago
Awakn’s second psychedelic therapy clinic to open in London
- Insight7 months ago
Microdosing: separating fact from fiction
- Events9 months ago
Wonderland: Miami to host world’s largest psychedelic conference
- News11 months ago
Heroic Hearts to research psilocybin treatment for brain injury in veterans
- Insight11 months ago
Mixing psychedelics with lithium poses significant risk of seizures
- Medicinal6 months ago
Ketamine-assisted therapy for alcohol addiction could save lives
- Policy6 months ago
Global coalition launches to push for psilocybin rescheduling